Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study

Ting-Yung Chang 1,2,3, Chi-Ting Lu 1,2, Hsin-Lei Huang 1,3, Ruey-Hsing Chou 1,2,4, Chun-Chin Chang 1,2, Chung-Te Liu 5,6, Po-Hsun Huang 1,2,3* and Shing-Jong Lin 1,2,7,8

1 Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, 2 Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 3 Department of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan, 4 Department of Critical Care Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 5 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, 6 Division of Nephrology, Department of Internal Medicine, Wan-Fang Hospital, Taipei Medical University, Taipei, Taiwan,
7 Taipei Heart Institute, Taipei Medical University, Taipei, Taiwan, 8 Heart Center, Cheng-Hsin General Hospital, Taipei, Taiwan

Background: Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM), who are at a greater risk of acute myocardial infarction (AMI) and sudden cardiac death. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce cardiovascular events and mortality in T2DM patients with a risk of cardiovascular disease. This study aimed to investigate the effect of SGLT2 inhibitor use on the adverse cardiovascular and renal outcomes in T2DM patients with AMI.

Methods: A total of 1,268 patients admitted to the Coronary Care Unit due to AMI were retrospectively screened. Patients taking SGLT2 inhibitors before or during the index AMI hospitalization were assigned as group 1. Patients who never received SGLT2 inhibitors were assigned as group 2. Patients in groups 1 and 2 were matched in a 1:2 ratio, and 198 T2DM patients with stabilized AMI were retrospectively enrolled for the final analysis.

Results: With a mean follow-up period of 23.5 ± 15.7 months, 3 (4.5%) patients in group 1 and 22 (16.7%) patients in group 2 experienced rehospitalization for acute coronary syndrome (ACS), while 1 (1.5%) patient in group 1 and 7 (5.3%) patients in group 2 suffered sudden cardiac death. The Kaplan–Meier curves demonstrated that the patients in group 1 had a lower risk of adverse cardiovascular outcomes. According to the multivariate analysis, the baseline estimated glomerular filtration rate (eGFR) (P = 0.008, 95% CI: 0.944–0.991) and the use of SGLT2 inhibitors (P = 0.039, 95% CI: 0.116–0.947)
were both independent predictors of adverse cardiovascular outcomes. On the other hand, the use of SGLT2 inhibitors was not associated with adverse renal outcomes.

**Conclusion:** In T2DM patients with stabilized AMI, the use of SGLT2 inhibitors was associated with a lower risk of adverse cardiovascular outcomes. In addition, the baseline renal function was also an independent predictor of adverse cardiovascular outcomes.

**Keywords:** diabetes, mortality, hospitalization, SGLT2 inhibitor, myocardial infarction

**INTRODUCTION**

Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) (1–3). Patients with T2DM are at a greater risk of acute myocardial infarction (AMI), heart failure, and sudden cardiac death (4–7). A report by the Global Registry of Acute Coronary Events has demonstrated that in CAD patients presented to hospitals, approximately 1 out of 4 has a history of T2DM, which shows the high co-occurrence rate of T2DM and CAD (8). In addition, previous studies have revealed that T2DM patients and CAD patients have a similar risk for sudden cardiac death and major adverse cardiovascular events (MACE) (9). Therefore, these patients are considered as a single population regarding their risk for sudden cardiac death and MACE (10, 11).

Sodium-glucose cotransporter (SGLT) 2 inhibitors comprise a novel class of oral hypoglycemic agents that has been shown to improve cardiovascular outcomes in patients with T2DM and heart failure (11–14). Recently, four cardiovascular outcome trials (CVOTs) have been conducted to explore the safety and efficacy of SGLT2 inhibitors on cardiovascular outcomes in T2DM patients with a high risk of cardiovascular events (EMPA-REG OUTCOME, DECLARE-TIMI 58, CANVAS, and VERTIS-CV) (15–18). Based on the data of these CVOTs, a meta-analysis concluded that SGLT2 inhibitors reduce the risk for cardiovascular events and mortality, especially in patients with both T2DM and CAD at baseline (19).

Based on these results, the 2019 European Society of Cardiology Guidelines on Diabetes and Cardiovascular Diseases listed SGLT2 inhibitors as one of the first-line glucose-lowering drugs for the treatment of T2DM patients with a high risk of cardiovascular disease (20). Nevertheless, although previous studies have shown the effect of SGLT2 inhibitors on diabetic patients at a high risk for cardiovascular disease, their effect on T2DM patients with stabilized AMI remains unknown. Therefore, this study was designed to investigate the effect of SGLT2 inhibitors on long-term cardiovascular and renal outcomes in T2DM patients after successful revascularization and stabilization of AMI.

**METHODS**

**Patient Population**

The present study was approved by the Institutional Review Board at Taipei Veterans General Hospital, Taipei, Taiwan (IRB no. 2022-01-033CC). The data used in this study were anonymized before analysis. From January 2016 to December 2020, a total of 1,268 patients admitted to the Coronary Care Unit due to AMI were retrospectively screened in this study. The exclusion criteria were as follows: (1) nondiabetic patients, (2) those with a baseline estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m², (3) failed revascularization or mortality during the indexed AMI episode. The two groups were matched in a 1:2 ratio. Adverse Cardiovascular outcome: rehospitalization for acute coronary syndrome and sudden cardiac death. Adverse Renal outcome: chronic dialysis, renal transplant, sustained reduction of ≥40% eGFR or sustained eGFR < 15 mL/min/1.73 m² for patients with eGFR ≥ 30 mL/min/1.73 m² at baseline.

**Data Collection**

The demographic profiles, comorbidities, laboratory data, and medication profiles of the participants were collected by the review of medical records. After being discharged, all of the
participants were scheduled to have a follow-up visit at the clinic 2 weeks later. The subsequent clinic visits were arranged at 1–3-month intervals, according to the discretion of the attending cardiologist. Data of the follow-up period were obtained by a medical record review and confirmed by a telephone interview. The composite of rehospitalization due to acute coronary syndrome (ACS) or sudden cardiac death was defined as an adverse cardiovascular outcome. Meanwhile, the composite of chronic dialysis, eGFR decline of ≥40%, or eGFR of <15 mL/min/1.73 m² was defined as an adverse renal outcome. Chronic dialysis was defined as dialysis treatment for more than 90 days (22).

Statistical Methods
All analyses were performed using SPSS statistical software, version 24.0 (SPSS, Inc., Chicago, IL, USA). Continuous variables were reported as the mean and standard deviation. Categorical variables were reported as frequencies and percentages. The chi-squared test was used to analyze categorical variables. Kaplan–Meier survival curves with the log-rank test were used to compare the occurrence of outcomes. The Cox proportional regression model was used to calculate the hazard ratio (HR) for the occurrence of outcomes.

RESULTS
Baseline Characteristics of the Study Subjects
This retrospective observational study included 198 AMI patients, among whom 66 patients were in group 1, and 132 patients were in group 2. The mean age of the patients was 66.1 ± 12.3 years old in group 1 and 67.7 ± 11.9 years old in group 2. The age, sex, comorbidities, and baseline eGFR were similar between the two groups. Notably, the percentage of patients with ST-elevation myocardial infarction, the thrombolysis in myocardial infarction (TIMI) risk score, and the volume of contrast medium used for revascularization were not significantly different between the two groups (Table 1). The above findings suggest that the two matched groups presented to the hospital with a similar severity of AMI. In group 1, the majority of SGLT2 inhibitor prescription was empagliflozin (78.8%), and 12 (18.2%) patients have been using the SGLT2 inhibitors before the indexe AMI hospitalization, with the mean duration of 12.8 ± 9.2 months.

Risk of Adverse Cardiovascular and Renal Outcomes
With a mean follow-up period of 23.5 ± 15.7 months (data not shown), 3 (4.5%) patients in group 1 and 22 (16.7%) patients in group 2 experienced rehospitalization due to ACS, while 1 (1.5%) patient in group 1 and 7 (5.3%) patients in group 2 experienced sudden cardiac death. Overall, the adverse cardiovascular outcomes occurred more frequently in group 2 (Table 1). To confirm the higher risk of adverse cardiovascular outcomes in group 2, Kaplan–Meier survival curves were constructed. The results demonstrated that the patients in group 1 had a longer adverse cardiovascular outcome-free survival than the patients in group 2 (Figure 2). The above findings suggest that post-AMI patients treated with SGLT2 inhibitors have a lower risk of adverse cardiovascular outcomes than those who are not taking this class of drug.

Regarding the adverse renal outcomes, there were 4 (6.1%) events in group 1 and 17 (12.9%) events in group 2; however, the difference was not significantly different between the two groups (Table 1). Similarly, the Kaplan–Meier survival curves showed that the adverse renal outcome-free survival was not significantly different between the two groups (Figure 3). The above findings suggest that SGLT2 inhibitors do not change the risk of adverse renal outcomes in post-AMI patients.

Table 1: Baseline characteristics of the study subjects.

|                     | Group 1 (n = 66) | Group 2 (n = 132) | P-value |
|---------------------|------------------|-------------------|---------|
| Age, years          | 66.1 ± 12.3      | 67.7 ± 11.9       | 0.382   |
| Male, n (%)         | 50 (75.8%)       | 95 (71.9%)        | 0.612   |
| Dyslipidemia, n (%) | 21 (31.8%)       | 40 (30.3%)        | 0.871   |
| Diabetes mellitus, n (%) | 66 (100.0%) | 132 (100.0%)     | -       |
| Congestive heart failure, n (%) | 5 (7.6%) | 6 (4.5%)     | 0.511   |
| Hypertension, n (%) | 44 (66.7%)       | 97 (73.5%)        | 0.323   |
| Coronary artery disease, n (%) | 66 (100.0%) | 132 (100.0%)   | -       |
| Chronic kidney disease, n (%) | 5 (7.6%) | 15 (11.4%)     | 0.464   |
| Old stroke, n (%)   | 4 (6.1%)         | 11 (8.3%)         | 0.777   |
| Atrial fibrillation, n (%) | 7 (10.6%) | 10 (7.6%)      | 0.591   |
| SGLT2 inhibitor     |                  |                   |         |
| Empagliflozin, n (%) | 52 (78.8%)      | 0 (0%)            | -       |
| Dapagliflozin, n (%) | 12 (18.2%)       | 0 (0%)            | -       |
| Canagliflozin, n (%) | 2 (3%)           | 0 (0%)            | -       |
| Insulin therapy, n (%) | 8 (12.1%)     | 20 (15.2%)        | 0.668   |
| Left ventricular ejection fraction, % | 52.0 ± 12.8 | 52.3 ± 10.6 | 0.873 |
| eGFR, mL/min/1.73 m² | 72.1 ± 22.7     | 67.7 ± 18.6       | 0.172   |
| ST elevation myocardial infarction, n (%) | 30 (45.5%) | 48 (36.4%) | 0.222 |
| TIMI risk score      | 3.8 ± 1.8        | 4.1 ± 1.5         | 0.282   |
| Contrast medium during revascularization, mL | 204.6 ± 97.9 | 217.1 ± 106.3 | 0.473 |
| Adverse cardiovascular outcomes, n (%) | 4 (6.1%) | 29 (22.0%) | 0.004  |
| Rehospitalization for ACS, n (%) | 3 (4.5%) | 22 (16.7%) | -       |
| Sudden cardiac death, n (%) | 1 (1.5%) | 7 (5.3%) | -       |
| Adverse renal outcomes, n (%) | 4 (6.1%) | 17 (12.9%) | 0.220  |

ACS: Acute coronary syndrome; eGFR, estimated glomerular filtration rate; SGLT2, sodium glucose cotransporter 2; TIMI, thrombolysis in myocardial infarction.
with an adverse cardiovascular event (12.1 vs. 37.6%, \( P = 0.004 \), Table 2).

To build the multivariate regression model, the candidate predictors were evaluated for their association with adverse cardiovascular outcomes using univariate Cox proportional regression analysis. The predictors with \( P \)-values of <0.05 were included in the multivariate Cox proportional regression model. Accordingly, age, baseline eGFR, and the use of SGLT2 inhibitors were included in the multivariate regression model.

The results demonstrated that only the baseline eGFR (\( P = 0.008 \), 95% CI: 0.944–0.991) and the use of SGLT2 inhibitors (\( P = 0.039 \), 95% CI: 0.116–0.947) remained significantly

| TABLE 2 | Comparison between patients with vs. without adverse cardiovascular events. |
|----------|---------------------------------------------------------------|
| Patients with an adverse CV event | Patients without an adverse CV event | \( P \)-value |
| \((n = 33)\) | \((n = 165)\) |
| Age (years) | 72.3 ± 14.6 | 66.8 ± 11.5 | 0.045 |
| Male (\(n\), %) | 22 (66.7%) | 132 (80%) | 0.402 |
| Dyslipidemia | 11 (33.3%) | 55 (33.3%) | 0.838 |
| Diabetes mellitus (\(n\), %) | 33 (100.0%) | 165 (100.0%) | - |
| CHF (\(n\), %) | 4 (12.1%) | 8 (4.8%) | 0.097 |
| Hypertension (\(n\), %) | 27 (81.8%) | 127 (77.0%) | 0.208 |
| CAD (\(n\), %) | 33 (100.0%) | 165 (100.0%) | - |
| CKD (\(n\), %) | 7 (21.2%) | 20 (12.1%) | 0.150 |
| Old stroke (\(n\), %) | 1 (3%) | 16 (9.7%) | 0.482 |
| Atrial fibrillation (\(n\), %) | 3 (9.1%) | 16 (9.7%) | 1.000 |
| LVEF (%) | 51.3 ± 9.8 | 52.1 ± 11.6 | 0.725 |
| eGFR (mL/min/1.73 m\(^2\)) | 58.0 ± 20.8 | 69.3 ± 20.3 | 0.004 |
| STEMI (%) | 11 (33.3%) | 70 (42.4%) | 0.565 |
| TIMI risk score (mean) | 4.3 ± 1.4 | 4.0 ± 1.6 | 0.274 |
| SGLT2 inhibitor | 4 (12.1%) | 62 (37.6%) | 0.004 |

ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; SGLT2, sodium-glucose cotransporter 2; STEMI, ST-elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.
associated with the risk of adverse cardiovascular outcomes (Table 3).

**DISCUSSION**

The main findings of this study were as follows: (1) In patients with T2DM and stabilized AMI, the use of SGLT2 inhibitors was associated with a lower risk of adverse cardiovascular outcomes. (2) Among diabetic patients with stabilized AMI, SGLT2 inhibitor use and a lower baseline renal function were both independent predictors of adverse cardiovascular outcomes. (3) The use of SGLT2 inhibitors was not significantly associated with adverse renal outcomes. These findings suggest that the use of SGLT2 inhibitors protects diabetic patients from AMI by reducing adverse cardiovascular events but does not change the risk of adverse renal outcomes in post-AMI patients.

Previous studies have demonstrated that in the early stage of AMI, SGLT2 inhibitor use reduces the myocardial infarct size through activation of signal transducer and activator of transcription 3 and downregulation of inflammatory responses in the infarcted myocardium (23). In addition, in diabetic mice, SGLT2 inhibitors reduce oxidative stress by decreasing the production of reactive oxygen species and the activity of nicotinamide-adenine dinucleotide phosphate (24, 25). Furthermore, SGLT2 inhibitors have also been shown to reduce oxidative stress through increasing endothelial nitric oxide synthase and nitric oxide formation in porcine endothelial cells (26).

Regarding atherosclerosis progression, previous studies have demonstrated that SGLT2 inhibitors suppress the transmigration of monocytes into the intima-intimal space (24, 25, 27). Moreover, SGLT2 inhibitors also reduce the number of atheroma plaques as well as the size and the surface area of atherosclerotic lesions in animal models of diabetes and atherosclerosis (24, 25, 28–30). Additionally, SGLT2 inhibitors have been shown to stabilize atherosclerotic plaques by reducing the number of macrophages and the cholesterol crystal content in the atherosclerotic plaques (24, 29). The abovementioned studies suggest that SGLT2 inhibitors may treat the infarcted myocardium by restoring endothelial function, decreasing oxidative stress, reducing inflammation, and inhibiting the evolution of monocytes to macrophages to foam cells. Furthermore, SGLT2 inhibitors may prevent the progression of coronary atherosclerosis by reducing the plaque burden, changing the plaque composition, and increasing the plaque stability.

**Effects of SGLT2 Inhibitors on Post-infarcted Adverse Cardiac Remodeling**

Following AMI, heart failure with adverse remodeling of left ventricle characterized by chamber dilatation and impaired cardiac function is the common outcome (31). In one recently published meta-analysis, including a total of 13 randomized controlled trials that evaluated the effects of SGLT2 inhibitors on cardiac remodeling in patients with T2DM and/or HF, SGLT2 inhibitors improved left ventricular (LV) ejection fraction, LV mass, LV mass index, LV end-systolic volume, LV end-systolic volume index, and E-wave deceleration time significantly (32). There were plausible effects of SGLT2 inhibitors on adverse cardiac remodeling. First, myocardial ischemia could impair cardiomyocyte autophagy, which has been shown an essential mechanism that protects against adverse cardiac remodeling (33). Recent experimental studies have indicated that SGLT2 inhibitors might exert cardioprotective effects by stimulating autophagy (34). Second, cardiac mitochondrial dysfunction during ischemia and reperfusion injury is a critical determinant of post-infarcted cardiac cell death, and is associated with future adverse cardiac remodeling (35). There have been several studies demonstrated that cardiac mitochondrial function could be improved by SGLT2 inhibitors (36–38). Taken together, reversed cardiac remodeling may be a mechanism responsible for the favorable clinical effects of SGLT2 inhibitor on patients with heart failure (39).

**Results of Previous Studies of SGLT2 Inhibitors to Treat Coronary Artery Disease**

The meta-analysis of the four major CVOTs mentioned above showed a 12% reduction of the risk for MACE in the group taking SGLT2 inhibitors (HR, 0.88; 95% CI: 0.82–0.94) (40). In particular, there was a 17% reduction in sudden cardiac deaths and a 12% reduction in myocardial infarctions. In this meta-analysis, the authors also analyzed the effects of SGLT2 inhibitors in those with vs. without cardiovascular disease at baseline. The results showed that the risk reduction of myocardial infarction in the secondary prevention cohort was more significant than that in the primary prevention cohort (HR: 0.86; 95% CI: 0.80–0.93 for secondary prevention; and HR: 0.94; 95% CI: 0.82–1.07 for primary prevention). The other two meta-analysis studies also revealed risk reductions of 18% and 21%, respectively, for cardiovascular mortality in the SGLT2 inhibitor-treated group (41, 42). In accordance with these previous studies, our results showed that the patients taking SGLT2 inhibitors had fewer adverse cardiovascular outcomes, including rehospitalization for ACS and sudden cardiac death. Since the study population consisted of patients with stabilized AMI, our results demonstrate the protective effect of SGLT2 inhibitors on the secondary prevention of AMI, which is in line with a previous report (40).

**Results of Previous Studies of SGLT2 Inhibitors to Treat Chronic Kidney Disease**

The meta-analysis of four CVOTs, including 38,723 participants with T2DM, demonstrated a risk reduction of 35% for end-stage renal disease in patients taking SGLT2 inhibitors (43). Nonetheless, another meta-analysis showed that while treatment with SGLT2 inhibitors reduced the risk of major renal outcomes by 46% in patients with macroalbuminuria and atherosclerotic cardiovascular disease, it had no significant effect on renal outcomes in the subgroup with eGFR <60 mL/min/1.73 m².
(HR: 0.74, 95% CI: 0.51–1.06) (44). In the current study, we did not observe a significant benefit of SGLT2 inhibitors on renal outcomes in diabetic patients with AMI. This finding could be explained by the small number of cases analyzed or the limited observation period.

In the past two decades, although the mortality due to AMI has improved (45, 46), the long-term cardiovascular mortality and post-AMI heart failure remain significant issues (45, 47). Thus, cardiac protection with early reperfusion to reduce the size of the myocardial infarct and the incidence of post-AMI cardiovascular adverse events are important topics to be studied. To the best of our knowledge, this is the first study showing that SGLT2 inhibitor use reduces the risk of adverse cardiovascular outcomes in T2DM patients with stabilized AMI.

This study has several limitations that must be addressed. First, due to the long period of enrollment, heterogeneity in treatment/stenting strategies may exist and confound the analysis. A second limitation is the single-center design and the relatively small number of included patients. A third limitation is that the physician skills regarding coronary revascularization were not controlled, which may also confound the analysis. Fourth, although a propensity score-adjusted analysis was employed to minimize the selection bias, remaining bias may still affect the analysis. Fifth, the retrospective nature of this study and the low number of events in each group limited further important subgroup analyses, such as an analysis based on the presence of absence of heart failure.

In conclusion, the findings of the present study might suggest that in T2DM patients with stabilized AMI, the use of SGLT2 inhibitors is associated with a lower risk of adverse cardiovascular outcomes, including rehospitalization for ACS and sudden cardiac death. Our study also demonstrates at least partly that the use of SGLT2 inhibitors could provide cardioprotection to T2DM patients with AMI. However, studies with a larger sample size are needed to verify these findings.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Institutional Review Board, Taipei Veterans General Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

T-YC and C-TLiu analyzed the data and drafted the manuscript. L-HL and R-HC collected and analyzed the data. C-CC and C-TLiu drew the tables and figures. P-HH and S-JL designed the study and revised the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported, in part, by research grants from the Ministry of Science and Technology of Taiwan (MOST 104-2314-B-075-047), the Novel Bioengineering and Technological Approaches to Solve Two Major Health Problems in Taiwan sponsored by the Taiwan Ministry of Science and Technology Academic Excellence Program (MOST 108-2633-B-009-001), the Ministry of Health and Welfare (MOHW 106-TDU-B-211-113001), Taipei Veterans General Hospital (V105C-0207, V106C-045), and Wan Fang Hospital, Taipei Medical University (110-SWF-02). These funding agencies had no influence on the study design, data collection or analysis, decision to publish, or preparation of the manuscript.

**REFERENCES**

1. Goldberg RB. Cardiovascular disease in diabetic patients. *Med Clin North Am.* (2000) 84:81–93. viii. doi: 10.1016/S0025-7125(05)70208-X

2. Simpfendorfer C. Efficacy of beta blockade, thrombolytic therapy, and coronary angioplasty in diabetic patients with coronary artery disease. *Cleve Clin J Med.* (1993) 60:145–9. doi: 10.2337/ccjm.60.2.145

3. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. *Diabetes*. (1974) 23:105–11. doi: 10.2337/diab.23.2.105

4. Yudkin JS, Oswald GA. Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction. *Diabetes Care.* (1988) 11:351–8. doi: 10.2337/diabcare.11.4.351

5. Behar S, Boyko V, Reicher-Reiss H, Goldbourt U. Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. *SPRINT Study Group Secondary Prevention Reinforcement Israeli Nifedipine Trial, Am Heart J.* (1997) 133:290–6. doi: 10.1016/S0002-8703(97)70222-9

6. Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. *Diabetes Care.* (1997) 20:704–8. doi: 10.2337/diabcare.20.5.704

7. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. *Diabetes Care.* (1998) 21:69–75. doi: 10.2337/diacare.21.1.69

8. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. *Arch Intern Med.* (2004) 164:1457–63. doi: 10.1001/archinte.164.13.1457

9. Zhou M, Liu J, Yao Y, Liu J, Hua Y, Smith SC Jr, et al. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the improving care for cardiovascular disease in patients with acute coronary syndrome project. *Cardiovasc Diabetol.* (2018) 17:147. doi: 10.1186/s12933-018-0793-x

10. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. *Endocr Pract.* (2017) 23:1–87. doi: 10.4188/EP171764.GL

11. Collet JP, Thiele H, Barbato E, Barthelmey O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in
patients presenting without persistent ST-segment elevation. *Eur Heart J.* (2021) 42:1289–367. doi: 10.1093/eurheartj/ehaa575

12. Lam CSP, Chandramouli C, Ahoaja V, Verma S. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. *J Am Heart Assoc.* (2019) 8:e013389. doi: 10.1161/JAHA.119.013389

13. McMurray JV, Solomon SD, Inzucchi SE, Kober L, Kjos LB, Martínez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med.* (2019) 381:1995–2008. doi: 10.1056/NEJMoa1911303

14. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med.* (2020) 383:1413–24. doi: 10.1056/NEJMoa2022190

15. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice. *Sci Rep.* (2022) 12:65. doi: 10.1038/s41598-022-8849-4

16. Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE(-/-) mice fed a western diet. *Diabetologia.* (2017) 60:364–76. doi: 10.1007/s00125-016-4158-3

17. Park SH, Belcastro E, Hasan H, Matsushita K, Marchandot B, Abbas M, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. *J Am Heart Assoc.* (2021) 10:e021959. doi: 10.1161/JAHA.120.021959

18. Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. *J Clin Invest.* (2018) 128:3716–26. doi: 10.1172/JCI120849

19. Croteau D, Luptak I, Chambers JM, Hobai I, Panagia M, Pimentel DR, et al. Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(-/-) Mice. *Mediators Inflamm.* (2016) 2016:305735. doi: 10.1155/2016/305735

20. Canoop JS, Jupin JA, Niese S, Kaltenbach T, Wanner C, et al. Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Effects on Mortality and Hospitalization. *Circulation.* (2021) 143:310–21. doi: 10.1161/CIRCULATIONAHA.120.051685

21. Hansson G, Libby P. Role of inflammation in atherogenesis in diabetic apolipoprotein E-deficient mice. *Eur J Pharmacol.* (2020) 875:137040. doi: 10.1016/j.ejphar.2020.137040

22. Park SH, Belcastro E, Hasan H, Matsushita K, Marchandot B, Abbas M, et al. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins. *Cardiovasc Diabetol.* (2022) 21:65. doi: 10.1186/s12933-021-01252-3

23. Liu Y, Xu J, Wu M, Xu B, Kang L. Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity. *Lipids Health Dis.* (2021) 20:5. doi: 10.1186/s12944-021-01430-9

24. Pocock SJ, Chang W, Ouyang X, Lei X, Wu M, Chen L, Wu Q, et al. The SGLT-2 Inhibitor Carvedilol Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice. *PLoS ONE.* (2015) 10:e0143396. doi: 10.1371/journal.pone.0143396

25. Park SH, Belcastro E, Hasan H, Matsushita K, Marchandot B, Abbas M, et al. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins. *Cardiovasc Diabetol.* (2022) 21:65. doi: 10.1186/s12933-021-01252-3

26. Liu Y, Xu J, Wu M, Xu B, Kang L. Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity. *Lipids Health Dis.* (2021) 20:5. doi: 10.1186/s12944-021-01430-9

27. Pennig J, Scherrer P, Gissler MC, Anto-Michel N, Hoppe N, Furer L, et al. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice. *Sci Rep.* (2019) 9:17937. doi: 10.1038/s41598-019-45224-9

28. Terasaki M, Hiromura M, Mori Y, Kohashi K, Nagashima M, Kushima H, et al. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage
47. Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM. National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010. *Circulation*. (2015) 128:2577–84. doi: 10.1161/CIRCULATIONAHA.113.003668

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Chang, Lu, Huang, Chou, Chang, Liu, Huang and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*